Stephen M. Monroe, Partner
Gretchen S. Swanson, Associate Editor
800-248-1668
Fax: 203-846-8300
pressreleases@levinassociates.com
Second Quarter Sees Venture Capitalists Still
Snapping Up Health Care, With $2.0 Billion Invested According To Jenks
Healthcare Business Report
NEW CANAAN, CT –July 1, 2004
– During the second quarter ended June 30, 2004, according to Jenks
Healthcare Business Report, venture capitalists pumped $2.0 billion into
111 investments in the health care markets, which showed sustained strength
for the second quarter in a row. Of twenty-three health care companies that
secured commitments of $30.0 million or more, seven companies boasted
financings of $50.0 million or more. This quarter the three largest deals
were made by American Esoteric Laboratories securing $70.0 million, Idun
Pharmaceuticals ($65.6 million) and Corus Pharmaceuticals ($60.0 million) in
venture financing.
The most active
venture capital firms this quarter, each investing in four or more
companies, numbered 18 and are listed below:
Venture Capital Firm
Number
of Health Care Investments
3i plc
8
Schroder
Ventures*
7
Burrill
& Co. Funds
6
OrbiMed
Advisors
6
Alta
Partners Funds
5
HBM
Partners
5
HealthCap Funds
5
MPM
Capital
5
New
Enterprise Associates
5
Nomura
Securities Funds
5
Novo A/S
5
TVM
Techno Venture Management
5
Abingworth Management Ltd.
4
Essex
Woodlands Healthcare Ventures
4
Bear
Stearns Health Innoventures
4
Prospect
Venture Partners
4
Versant
Ventures
4
*Schroder
Ventures includes (5) investments made by Schroder Ventures Life
Sciences as well as (2) made by Schroder ISF Swiss Small & Mid Cap
Equity Funds.
The average size of health
care venture capital investments during second quarter 2004 was $18.02
million, representing a 14% decrease compared with the average investment
size of $20.9 during the first quarter 2004. Jenks reported that
during the quarter ended March 30, 2004, 97 deals were made, or 13% fewer
than the current quarter, totaling $2.03 billion, negligibly more than the
current quarter.
Pharmaceutical
companies are receiving continued support from the venture capital
community, while biopharmaceutical, biotechnology and medical device
companies are also capturing a nice slice of health care dollars.
“Investors know that cutting-edge health care companies will provide
excellent future returns,” commented Stephen M. Monroe, managing editor at
Irving Levin Associates, Inc., “and we are seeing more health care companies
that develop products or achieve clinical advancements through high
technology, resulting in a combined appeal to investors.”
About Jenks Healthcare
Business Report:
The monthly
newsletter Jenks Healthcare Business Report andits companion
annual report, The Health Care Venture Capital Report, are published
by Irving Levin Associates, Inc., a leading health care financial publisher
established in 1948. The Firm has headquarters in New Canaan, CT and is
online at
www.levinassociates.com. This privately held corporation publishes
research reports and newsletters, and maintains merger and acquisition
databases, on the health care and senior housing markets. For more
information on Jenks Healthcare Business Report, please call
1-800-248-1668.
Click here to get more information or to order any of our
Publications.
Since 1948, Irving
Levin Associates, Inc. has been the leading source of information
and investment research on mergers and acquisitions in the
Behavioral Health Care, Biotech, e-Health, Home Health Care,
Hospitals, Laboratories, MRI and Dialysis, Long Term Care, Managed
Care, Medical Devices, Pharmaceuticals, Physician Medical Groups,
Rehabilitation and other health care markets.